The drug repurposing service providers market is projected to grow at an annualized rate of 14.7%..

Roots Analysis has done a detailed study on Drug Repurposing Service Providers Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 250+ page report, which features 100+ figures and 140+ tables, please visit this link
Key Market Insights 
  • More than 60 industry players across the world are presently engaged in providing services for the repurposing of therapeutics
  • The dataset features a variety of CRO, big data / analytics and technology-based service providers, offering repurposing services by using different type of repurposing approaches and drug molecules
  • Over 1,700  discontinued clinical studies of therapeutics can be considered as potential candidates for repurposing
  • In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, service providers are actively exploring the therapeutic potential of the existing approved drugs by providing the necessary support to drug developers in identifying / predicting prospective drug candidates for repurposing.
  • Over time, recent initiatives have been undertaken by big pharma players across the world for the discovery and development of repurposed drugs
  • Several organizations have extended financial support to aid research efforts in this domain; the current focus is on investigation of novel immune checkpoint pathways / targets for coronavirus disease
  • The growing interest in this field is also reflected by the 10+ partnerships have been signed in the last three years, involving both international and indigenous stakeholders
  • The future market, based on the revenue generation potential of repurposed drugs, is anticipated to be distributed across different disease areas and key geographical regions
  • In the long term, the opportunity is likely to be segmented across type of repurposing approaches, purpose of repurposing and type of drug molecule
For more information, please visit https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html
 
Table of Contents
 
1.         PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION
3.1.       Chapter Overview
3.2.       Overview of Drug Repurposing
3.2.1     History of Drug Repurposing
3.2.2     Strategies for Drug Repurposing
3.3.       Repurposing versus the Traditional Drug Discovery
3.4.       Benefits and Challenges Associated with Drug Repurposing       
3.5.       Drug Repurposing Service Providers
4.         MARKET LANDSCAPE
4.1.       Chapter Overview         
4.2.       Drug Repurposing Service Provider: Overall Market Landscape of Contract Research Organizations (CROs)
4.2.1.    Analysis by Year of Establishment
4.2.2.    Analysis by Company Size
4.2.3.    Analysis by Location of Headquarters
4.2.4.    Analysis by Company Size and Location of Headquarters
4.2.5.    Analysis by Type of Drug Molecule
4.2.6.    Analysis by Status of Drug
4.2.7.    Analysis by Repurposing Approach
4.2.8.    Analysis by Services Offered
4.3.       Drug Repurposing Service Provider: Overall Market Landscape of Big Data / Analytics Service Providers
4.3.1.    Analysis by Year of Establishment
4.3.2.    Analysis by Company Size
4.3.3.    Analysis by Location of Headquarters
4.3.4.    Analysis by Company Size and Location of Headquarters
4.3.5.    Analysis by Technology Specifications
4.3.6.    Analysis by Type of Drug Molecule
4.3.7.    Analysis by Status of Drug
4.3.8.    Analysis by Repurposing Approach
4.3.9.    Analysis by Services Offered
4.4.       Drug Repurposing Service Provider: Overall Market Landscape of Technology Providers
4.4.1.    Analysis by Year of Establishment
4.4.2.    Analysis by Company Size
4.4.3.    Analysis by Location of Headquarters
4.4.4.    Analysis by Company Size and Location of Headquarters
4.4.5.    Analysis by Technology Specifications
4.4.6.    Analysis by Type of Drug Molecule
4.4.7.    Analysis by Status of Drug
4.4.8.    Analysis by Repurposing Approach
4.2.9.    Analysis by Services Offered
 
5.         ROLE OF NON-PROFIT / ACADEMIC ORGANIZATIONS
5.1.       Chapter Overview
5.2.       Drug Repurposing Service Providers: List of Non-Profit Organizations
5.3.       Stakeholder Profiles
5.3.1.    Cures Within Reach
5.3.2.    GlobalCures
5.3.3.    Anticancer Fund
5.3.4.    National Center for Advancing Translational Sciences
5.4.       Drug Repurposing Service Providers: List of Academic Organizations
6.         COMPANY PROFILES 
6.1.       Chapter Overview
6.2.       Company Profiles for CROs
6.2.1.    Auxiliis Pharma
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Future Outlook
6.2.2.    ChemBio Discovery Solutions
6. 2.2.1. Company Overview
6. 2.2.2. Service Portfolio
6. 2.2.3. Future Outlook
6.2.3.    GVK BIO
6.2.3.1. Company Overview
6.2.3.2. Technology Overview
6.2.3.3. Service Portfolio
6.2.3.4. Future Outlook
6.2.4.    Iris Pharma
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Future Outlook
6.2.5.    Physiogenex
6.2.5.1. Company Overview
6.2.5.2. Service Portfolio
6.2.5.3. Future Outlook
6.3.       Company Profiles for Big Data / Analytics Service Providers
6.3.1.    Excelra
6.3.1.1. Company Overview
6.3.1.2. Technology Overview
6.3.1.3. Service Portfolio
6.3.1.4. Future Outlook
6.3.2.    Smart Pharma
6.3.2.1. Company Overview
6.3.2.2. Technology Overview
6.3.2.3. Service Portfolio
6.3.2.4. Future Outlook
6.4.       Company Profiles for Technology Providers
6.4.1.    Lantern Pharma
6.4.1.1. Company Overview
6.4.1.2. Technology Overview
6.4.1.3. Service Portfolio
6.4.1.4. Future Outlook
6.4.2.    Panxome
6.4.2.1. Company Overview
6.4.2.2. Technology Overview
6.4.2.3. Service Portfolio
6.4.2.4. Future Outlook
6.4.3.    Pharmacelera
6.4.3.1. Company Overview
6.4.3.2. Technology Overview
6.4.3.3. Service Portfolio
6.4.3.4. Future Outlook
           
6.4.4.    Socium
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Future Outlook
6.4.5.    SOM Biotech
6.4.5.1. Company Overview
6.4.5.2. Technology Overview
6.4.5.3. Service Portfolio
6.4.5.4. Future Outlook
           
7.         PARTNERSHIPS
7.1.       Chapter Overview
7.2.       Partnership Models
7.3.       Drug Repurposing Service Providers: List of Partnerships
7.3.1.    Analysis by Year of Partnership
7.3.2.    Analysis by Type of Partnership
7.3.3.    Analysis by Year and Type of Partnership
7.3.4.    Analysis by Type of Technology / Platform Used
7.3.5.    Analysis by Therapeutic Area
7.3.6.    Geographical Analysis
7.3.6.1. Continent-wise Distribution
7.3.6.2. Country-wise Distribution
8.         BIG PHARMA INITIATIVES
8.1.       Chapter Overview
8.2.       List of Drug Repurposing Initiatives of Big Pharma Players
8.2.1.    Analysis by Number of Initiatives
8.2.2.    Analysis by Year of Initiative
8.2.3.    Analysis by Type of Initiative
8.2.4.    Analysis by Therapeutic Area
8.2.5.    Analysis by Type of Drug Molecule
8.2.6.    Big Pharma Activity: Analysis by Year of Initiative and Company
8.2.7.    Big Pharma Activity: Analysis by Type of Drug Molecule and Company
8.3.       Competitive Benchmarking of Big Pharma Players
8.3.1.    Big Pharma Investment Summary
8.4.       Initiatives Undertaken by Leading Players
8.4.1.    Initiatives Undertaken by AbbVie
8.4.1.1. In-House Initiatives
8.4.2.    Initiatives Undertaken by Astellas Pharma
8.4.2.1. Initiatives in Collaboration with Other Stakeholders
8.4.2.2. Recent Regulatory Approvals of Repurposed Drugs
8.4.3.   Initiatives Undertaken By AstraZeneca
8.4.3.1. In-House Initiatives
8.4.3.2. Initiatives in Collaboration with Other Stakeholders
8.4.4.    Initiatives Undertaken by Bayer
8.4.4.1. Initiatives in Collaboration with Other Stakeholders
8.4.5.    Initiatives Undertaken by Boehringer Ingelheim
8.4.5.1. Initiatives in Collaboration with Other Stakeholders
8.4.5.2. Recent Regulatory Approvals of Repurposed Drugs
8.4.6.    Initiatives Undertaken by Eli Lilly
8.4.6.1. Initiatives in Collaboration with Other Stakeholders
8.4.6.2. Recent Regulatory Approvals of Repurposed Drugs
8.4.7.    Initiatives Undertaken by Gilead Sciences
8.4.7.1. Recent Regulatory Approvals of Repurposed Drugs
8.4.8.    Initiatives Undertaken by GSK
8.4.8.1. In-House Initiatives
8.4.8.2. Initiatives in Collaboration with Other Stakeholders
8.4.9.    Initiatives Undertaken by Novartis
8.4.9.1. In-House Initiatives
8.4.9.2. Initiatives in Collaboration with Other Stakeholders
8.4.9.3. Recent Regulatory Approvals of Repurposed Drugs
8.4.10.  Initiatives Undertaken by Roche
8.4.10.1. In-House Initiatives
8.4.10.2. Initiatives in Collaboration with Other Stakeholders
8.4.11.  Initiatives Undertaken by Sanofi
8.4.11.1. In-House Initiatives
8.4.11.2. Recent Regulatory Approvals of Repurposed Drugs
8.5.       Other Big Pharma Players
8.5.1.    Initiatives Undertaken by Pfizer
8.5.1.1. Initiatives in Collaboration with Other Stakeholders
9.          CASE STUDY: DISCONTINUED DRUG DEVELOPMENT PROGRAMS
9.1.        Chapter Overview
9.2.        Scope and Methodology
9.3.        Drug Repurposing: Discontinued Clinical Trials
9.3.1.     Analysis by Trial Status
9.3.2.     Analysis by Trial Phase
9.3.3.     Analysis by Cause of Discontinuation of Clinical Research
9.3.4.     Analysis by Therapeutic Area
9.3.5.     Analysis by Trial Status and Location of Trial Site
9.3.6.     Analysis by Phase Distribution versus Cause of Discontinuation of Clinical Research
9.3.7.    Analysis by Trial Phase and Target Therapeutic Area
9.3.8.    Analysis by Cause of Discontinuation of Clinical Research and Target Therapeutic Area
9.4.       Discontinued Clinical Trials Analysis: Key Therapeutic Area
9.4.1.    Discontinued Clinical Trials: Oncology Disorders
9.4.1.1. Analysis by Trial Status
9.4.1.2. Analysis by Trial Phase
9.4.1.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.1.4. Analysis by Trial Status and Location of Trial Site
9.4.2.    Discontinued Clinical Trials Analysis: CNS Disorders
9.4.2.1. Analysis by Trial Status
9.4.2.2. Analysis by Trial Phase
9.4.2.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.2.4. Analysis by Trial Status and Location of Trial Site
9.4.3.    Discontinued Clinical Trials Analysis: Metabolic Disorders 
9.4.3.1. Analysis by Trial Status
9.4.3.2. Analysis by Trial Phase
9.4.3.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.3.4. Analysis by Trial Status and Location of Trial Site
9.4.4.    Discontinued Clinical Trials Analysis: Infectious Disorders    
9.4.4.1. Analysis by Trial Status
9.4.4.2. Analysis by Trial Phase
9.4.4.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.4.4. Analysis by Trial Status and Location of Trial Site
9.4.5.    Discontinued Clinical Trials Analysis: Autoimmune Disorders     
9.4.5.1. Analysis by Trial Status
9.4.5.2. Analysis by Trial Phase
9.4.5.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.5.4. Analysis by Trial Status and Location of Trial Site
9.5.       List of Potential Drug Candidates
10.        COST SAVING ANALYSIS
10.1.     Chapter Overview
10.2.     Cost Saving Potential
10.2.1.   Opinion of Industry Experts
10.3.      Key Therapeutic Areas
10.3.1.   Oncology Disorders
10.3.2.   Neurological Disorders
10.3.3.   Metabolic Disorders
10.3.4.   Infectious Diseases
10.3.5.   Rare Disorders
10.4.      Concluding Remarks
11.        MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1.     Chapter Overview
11.2.     Key Assumptions
11.3.      Forecast Methodology
11.4.     Overall Drug Repurposing Services Market, 2020-2030
11.4.1.  Drug Repurposing Services Market: Distribution by Type of Drug Molecule, 2020, 2025 and 2030
11.4.1.1. Drug Repurposing Services Market for Small Molecules, 2020-2030
11.4.1.2. Drug Repurposing Services Market for Biologics, 2020-2030
11.4.2.  Drug Repurposing Services Market: Distribution by Type of Repurposing Approach, 2020-2030
11.4.2.1. Drug Repurposing Services Market using Disease-Centric Approach, 2020-2030
11.4.2.2. Drug Repurposing Services Market using Target-Centric Approach, 2020-2030
11.4.2.3. Drug Repurposing Services Market using Drug-Centric Approach, 2020-2030
11.4.3.   Drug Repurposing Services Market: Distribution by Therapeutic Area, 2020, 2025 and 2030
11.4.3.1. Drug Repurposing Services Market for Different Therapeutic Area, 2020-2030
11.4.3.2. Drug Repurposing Services Market for Same Therapeutic Area, 2020-2030
11.4.4.   Drug Repurposing Services Market: Distribution by Geography, 2020-2030
11.4.4.1. Drug Repurposing Services Market in North America, 2020-2030
11.4.4.2. Drug Repurposing Services Market in Europe, 2020-2030
11.4.4.3. Drug Repurposing Services Market in Asia Pacific and RoW, 2020-2030
12.          COVID-19 IMPACT ON DRUG REPURPOSING SERVICE PROVIDERS MARKET
12.1.       Chapter Overview
12.2.       Current Opinions and Recuperative Initiatives of Key Players
12.2.1.    Excelra
12.2.2.    GVK Bio
12.2.3.    Biovista
12.2.4.    Evotec
12.3.       Recuperative Strategies for Service Providers
12.3.1.    Strategies for Implementation in the Short / Mid Term
12.3.2.    Strategies for Implementation in the Long Term
13.        RECENT ADVANCEMENTS AND TRENDS IN OUTSOURCING OF DRUG REPURPOSING
13.1.     Chapter Overview
13.2.     Shift from One-Time Contracts to Strategic Partnerships
13.3.     Adoption of New and Innovative Technologies
13.3.1.  Artificial Intelligence
13.3.2.  Next Generation Drug Repurposing Techniques
13.4.     Focus on Niche Therapeutic Areas
13.5.     Increase in Financial Inflow and Outsourcing Budgets
14.        INTERVIEW TRANSCRIPTS
14.1.     Chapter Overview
14.2.     Nandu Gattu (Senior Vice President, Excelra)
15.        APPENDIX 1: LIST OF POTENTIAL DRUG-INDICATION CANDIDATES FOR DRUG                   REPURPOSING
16.        APPENDIX 2: TABULATED DATA
17.        APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS
 
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]

Presently, over 65 companies claim to offer drug repurposing-related services to the global pharmaceutical industry; interestingly, the majority (>55%) of such service providers firms are based in Europe, claims Roots Analysis
 
Repurposing of marketed / shelved / pipeline candidates for the treatment of diseases (different from original target indications) has emerged as a viable business strategy. The rising popularity of this approach can further be attributed to various benefits, such as reduced development timelines, decreased investments and relatively higher success rates (considering that the safety profiles of such candidates have already been established).
 
To order this 250+ page report, which features 100+ figures and 140+ tables, please visit this link
 
The USD 1.2 billion (by 2030) financial opportunity within the drug repurposing service providers market has been analyzed across the following segments:

Type of Repurposing Approaches

Disease-centric approach

Target-centric approach

Drug-centric approach

Therapeutic Area

Same Therapeutic Area

Different Therapeutic Area

Type of Drug Molecule

Biologics

Small Molecule

Key Geographical Region

North America

Europe

Asia-Pacific

 
The Drug Repurposing Service Providers Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: 

Auxillis Pharma

ChemBio Discovery Solutions

Excelra

GVK Bio

Iris Pharma

Lantern Pharma

PanXome

Pharmacelera

Physiogenex

Smart Pharma

Socium

SOM Biotech

 
Table of Contents
 
1. Preface

2. Executive Summary

3. Introduction


4. Market Landscape


5. Role of Non-Profit / Academic Organizations
 
6. Company Profiles 


7. Partnerships 


8. Big Pharma Initiatives 


9. Case Study: Discontinued Drug Development Programs


10. Cost Saving Analysis


11. Market Forecast and Opportunity Analysis


12.  Covid-19 Impact on Drug Repurposing Service Providers Market


 13. Recent Advancements and Trends in Outsourcing of Drug Repurposing
  
 14. Interview Transcripts
  15. Appendix 1: List of Potential Drug-Indication Candidates for Drug Repurposing
  16. Appendix 2: Tabulated Data
  17. Appendix 3: List of Companies and Organizations
  
 To purchase a copy, please visit https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html
  
 Contact Details
 Gaurav Chaudhary
 +1 (415) 800 3415
 [email protected] 
 

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
880 Posts

Made with by Mamby